A new item has been added to the shopping cart


Tell to a friend

Your Name:
E-mail of your friend:
Captcha CAPTCHA code
Enter the text in the image above


Already a subscriber? Log in now for online Access.


Artículo Tomo 71, Número. 3, Abril 2018

Archivos Españoles de Urología

The role of corticoids in the management of advanced prostate cancer.

Authors: Aránzazu González-del-Alba Baamonde y Elena Sevillano Fernández.

Arch. Esp. Urol. 2018; 71 (3): 281-287

Vol. 71, Number. 3, April 2018

Prostate cancer is the most frequent malignant tumor in males in developed countries and represents the second cause of cancer death. Over the last years, the number of treatments available for patients with advanced prostate cancer has improved significantly, achieving better disease control and notably better overall survival (1).

Corticosteroids have been extensively used in the treatment of castration resistant prostate cancer due to their palliative benefits on symptoms secondary to their potent anti-inflammatory activity and their demonstrated antitumor activity. At present time, we have a wide therapeuadretic arsenal for patients with metastatic prostate cancer and concomitant medication with corticosteroids may counteract adverse events of the main validated therapies.

Nevertheless, long term exposition to corticosteroid treatment required by prostate cancer patients may have negative implications in terms of development of potential adverse events and, in certain cases, even facilitating disease progression.


Only subscribers

Copyright © 2015 | Valid support N°12/08-W-CM | ISSN-ONLINE: 1576-8260 |